Exosome Proteomics of <scp> SOD1 <sup>D90A</sup> </scp> Mutation Suggest Early Disease Mechanisms, and <scp>FN1</scp> as a Biomarker
Exosome proteomics offer a powerful approach to interrogate disease-specific or disease-related proteins that become present in the blood. This helps define the perturbed cellular events with respect to disease progression and reveal potential pharmacokinetic biomarkers. We find FN1 levels to increase with disease progression, suggesting it may be a pharmacokinetic biomarker, especially for ALS patients with prominent UMN loss.
Authors
- P. Hande Özdi̇nler (ORCID: https://orcid.org/0000-0003-4125-6013)
- A. Nazlı Başak (ORCID: https://orcid.org/0000-0001-6977-2517)
- Mukesh Gautam (ORCID: https://orcid.org/0000-0003-0571-5825)
- Melda Yardimoğlu Yilmaz (ORCID: https://orcid.org/0000-0001-5463-2634)
- Aslıhan Günel (ORCID: https://orcid.org/0000-0001-5301-2628)
- Halil Atilla Idrısoğlu
- Ali Laith
Institutions
- Northwestern University (US)
- Koç University (TR)
- Ahi Evran University (TR)
- Kocaeli Üniversitesi (TR)
- Istanbul University (TR)
Publication Details
- Journal
- Annals of Clinical and Translational Neurology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1002/acn3.70208
- Citations
- 1
- Primary Topic
- Amyotrophic Lateral Sclerosis Research
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- Les Turner ALS Foundation
- Northwestern University